Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Aurora, Colorado 80045


Purpose:

Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the Food and Drug Administration (FDA) to treat HIV infection. When darunavir and ritonavir are given with pravastatin, they can increase the blood levels of pravastatin. The degree of this interaction varies from person to person. The way that darunavir and ritonavir interact with pravastatin may be affected by a person's genetic make-up. Genetic factors (or DNA) are those that people are born with and that make each person unique. Genetic differences are the reason why one person's body traits such as height and hair color are different from another person's body traits. Genetic differences can also affect the way a medication works in the body or the way two medications interact in the body. The purpose of this clinical study is to determine if a person's genetic make-up affects the way darunavir and ritonavir interact with pravastatin in the body.


Criteria:

Inclusion Criteria: - Healthy, HIV-negative volunteers Exclusion Criteria: - Currently active or chronic cardiovascular, hepatic, renal, pancreatic, gastrointestinal, neurologic, hematologic, psychiatric, metabolic, respiratory, inflammatory, or infectious disease - Chronic pancreatitis - History of rhabdomyolysis - History of statin-associated myopathy - Active malignancy - History of significant skin disease, food allergy, drug allergy, dermatitis, eczema, psoriasis - Pregnancy/breastfeeding - HIV positive and/or AIDS - serum creatinine grade 1 or greater (≥ 1.1 x upper limit of laboratory normal range [ULN]); - hemoglobin grade 1 or greater (≤ 10.9 g/dL); - platelet count grade 1 or greater (≤ 124.999 x 109/L); - absolute neutrophil count grade 1 or greater (≤ 1.3 x 109/L); - aspartate aminotransferase (AST) or alanine aminotransferase (ALT) grade 1 or greater (≥ 1.25 x ULN); - total bilirubin grade 1 or greater (≥ 1.1 x ULN) - serum lipase grade 1 or greater (≥ 1.1 x ULN) - serum amylase grade 1 or greater (≥ 1.1 x ULN) - any other laboratory abnormality of grade 2 or above


NCT ID:

NCT00630734


Primary Contact:

Principal Investigator
Christina L Aquilante, PharmD
University of Colorado, Denver


Backup Contact:

N/A


Location Contact:

Aurora, Colorado 80045
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.